home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

22.28 +0.15 (+0.68%)

Streaming Delayed Price Updated: 10:25 AM EDT, Apr 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

35 36 Next >

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

January 26, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Which stocks are moving after the closing bell on Friday? ↗

January 23, 2026

Via Chartmill

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

January 23, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

SRPT Stock Tumbles 12% On Lackluster Preliminary Revenue Numbers Due To Elevidys Safety Concerns ↗

January 12, 2026

Via Stocktwits

2 Beaten-Down Stocks That Could Sink Even More in 2026 ↗

January 21, 2026

Don't catch a falling knife.

Via The Motley Fool

Topics Death

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

January 12, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease

January 07, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 31, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Why Is SRPT Stock Falling Today? ↗

December 11, 2025

Sarepta Therapeutics announced a debt refinancing plan totaling about $291 million.

Via Stocktwits

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

December 11, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Dyne Therapeutics (DYN) Navigates a Paradoxical Day: Positive Clinical Data Overshadowed by Dilution Fears

December 09, 2025

New York, NY – December 9, 2025 – Dyne Therapeutics (NASDAQ: DYN) found itself in an unusual spotlight today, emerging as a significant market mover, albeit in a direction that belied ostensibly...

Via MarketMinute

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an...

Via MarketMinute

How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗

December 02, 2025

Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam.

Via Investor's Business Daily

Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys ↗

November 25, 2025

The data from the study cohort will be used to determine whether administering sirolimus before and after the ELEVIDYS infusion can help reduce acute liver injury, the company said.

Via Stocktwits

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

November 25, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

November 24, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Tech Edges Up Ahead Of Nvidia's Earnings, Bitcoin Sinks Below $90,000: What's Moving Markets Wednesday? ↗

November 19, 2025

All eyes are on Nvidia Corp. (NASDAQ:NVDA) as the world's most valuable company prepares to report third-quarter earnings after the close, a pivotal moment that could steer

Via Benzinga

Sarepta Stock Slides Premarket After New FDA Warning Shrinks Market For Its $3.2M DMD Gene Therapy ↗

November 17, 2025

FDA added a boxed warning to Elevidys after two pediatric deaths and imposed stricter monitoring rules.

Via Stocktwits

Topics Death

2 Beaten-Down Stocks to Avoid Right Now ↗

November 15, 2025

There might be plenty more downside for these biotechs.

Via The Motley Fool

Topics Death

Sarepta Shares Jump After FDA Approves Updated Elevidys Label ↗

November 14, 2025

Sarepta Therapeutics shares jumped after the FDA issued a new boxed warning for Elevidys.

Via Benzinga

Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information

November 14, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 11, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

November 05, 2025

Via Benzinga

Analyst Ratings Send Ripples Through Markets: Sarepta's Resilience vs. Pinterest's Plunge

November 05, 2025

The financial markets are a complex ecosystem, constantly reacting to a myriad of inputs, from macroeconomic data to geopolitical shifts. Among the most closely watched catalysts are the pronouncements...

Via MarketMinute

This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗

November 05, 2025

Via Benzinga

Sarepta Therapeutics Shares Plummet as Key DMD Treatments Miss Primary Endpoint in Late-Stage Trial

November 04, 2025

Sarepta Therapeutics Inc. (NASDAQ: SRPT) experienced a dramatic downturn in its stock valuation today, November 4, 2025, following the announcement of disappointing results from a pivotal late-stage...

Via MarketMinute

Topics Death

Which stocks are experiencing notable movement on Tuesday? ↗

November 04, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.

Via Chartmill

Gold Falls Over 1%; Uber Shares Decline After Q3 Results ↗

November 04, 2025

Via Benzinga

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance ↗

November 04, 2025

Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid Elevidys sales weakness.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com